^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

    Excerpt:
    ...Cohort A：EGFR T790M negative, MET amplification,(...
    Trial ID:
    NCT06109558
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

    Excerpt:
    ...Prevalence of MET amplification by MET FISH`Concordance of MET amplification between MET FISH testing and ddPCR blood testing`Prevalence of MET overexpression by MET IHC testing.`...
    Trial ID:
    GPS
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Med Insights Oncol
    Title:

    First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

    Published date:
    11/11/2022
    Excerpt:
    Between January 1, 2016 and October 31, 2020, a consecutive of 56 EGFR-mutant lung cancer patients treated with osimertinib as first-line therapy at Daping Hospital (Chongqing, China) were retrospective screened....A total of 21 patients underwent repeated NGS tests upon osimertinib resistance. MET amplification was the most common resistance mechanism (6/21, 28.6%), followed by C797S mutation (5/21, 23.8%).
    DOI:
    10.1177/11795549221134735
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Manag Res
    Title:

    Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer

    Published date:
    02/25/2021
    Excerpt:
    ...40 patients were proven to have EGFR T790 M by tumour biopsy in 16 patients and liquid biopsy in 24 patients after acquiring drug resistance to the first generation of EGFR-TKIs. All of these patients received osimertinib as second-line therapy and reached a PFS of 3–39 months for osimertinib. Ten patients underwent rebiopsy, including lung and lymph node biopsy, to analyse resistance-related mutations, including C797S and MET, by NGS panel....EGFR C797S mutation and MET amplification are leading mechanisms for osimertinib resistance in lung cancer.
    DOI:
    10.2147/CMAR.S292342